Transgenic tau models

These models recapitulate the tau pathology found in Alzheimer’s disease and primary tauopathies like frontotemporal dementia.

Sylics offers services with several different tau amyloid models. The choice of the best model depends on many factors, but most models present with neurofibrillary tangles, inflammation, and behavioral deficits.

Feel free to contact us anytime. One of our scientists will contact you within 24 hours to discuss your research needs.

Transgenic tau models that Sylics offers:

JNPL3

PS19

Humanized MAPT

Viral vector

Seeding Tau models

Tau pathology

Tau is encoded by the microtubule-associated protein tau (MAPT) gene. This protein aggregates intracellularly in Alzheimer’s disease (AD), frontotemporal dementia (FTD), and other tauopathies. Examples of these tauopathies include frontotemporal lobar degeneration (FTLD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Pick’s disease (PiD). Tau pathology in AD and other tauopathies is strongly associated with neurodegeneration and clinical symptoms.

Tau pathology in different tauopathies.

Transgenic mouse models of tau pathology

Mice that overexpress human tau with FTD-associated MAPT mutations display abundant tau pathology, neuroinflammation, neurodegeneration, and behavioral impairments. These models are therefore popular models to test therapeutic interventions for AD and other tauopathies.

Transgenic models that overexpress mutated human tau (MAPT*P301S or MAPT*P301L) show phosphorylated tau staining as detected by an AT8 antibody.
Gait analysis using the Catwalk detects motor function deficits in tau transgenic mice (MAPT*P301L)

Behavioral deficits

We have extensive experience with behavioral testing of several transgenic tau models. For example, we detect a progressive reduction in grip strength of mice expressing tau with a P301S mutation from 3.5 months of age onwards. In JNPL3 (P301L) mice we detect  changes in gait and footprint size with the Catwalk system at 6 months of age. By 10 months or older, these mice show profound motor function deficits.

Biological readouts

The number of tau inclusions and associated neuroinflammation or neurodegeneration can be quantified after immunohistochemical (IHC) staining of brain slices. In addition, we measure (phosphorylated) tau levels in the brain, cerebrospinal fluid, and blood using ultra-sensitive immunoassays. Neurodegeneration can also be detected by measuring neurofilament light chain (NfL) levels in the blood, using the ultrasensitive SIMOA immunoassay.

More information

Please reach out to us if you want to learn more about our Transgenic tau models solutions. We will contact you within 1 business day.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.